| Migraine Disorders
Ajovy vs Depakote
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Ajovy vs Depakote with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDepakote has a higher rate of injection site reactions vs Ajovy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Depakote but not Ajovy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ajovy
Depakote
At A Glance
SC injection
Monthly or every 3 months
CGRP antagonist
Oral
Daily in divided doses
Valproate anticonvulsant
Indications
- Migraine Disorders
- Episodic migraine
- Bipolar Disorder
- Complex partial seizures
- Absence Epilepsy
- Migraine Disorders
Dosing
Migraine Disorders 225 mg SC monthly or 675 mg SC quarterly (three consecutive 225 mg injections) into abdomen, thigh, or upper arm.
Episodic migraine Pediatric patients 6 to 17 years weighing 45 kg or more: 225 mg SC monthly.
Bipolar Disorder 750 mg/day initially in divided doses, titrated rapidly to clinical response; max 60 mg/kg/day; oral.
Complex partial seizures 10-15 mg/kg/day initially, increased by 5-10 mg/kg/week to optimal response; max 60 mg/kg/day; divide doses if total daily dose exceeds 250 mg; oral.
Absence Epilepsy 15 mg/kg/day initially, increased at one-week intervals by 5-10 mg/kg/day until seizures are controlled; max 60 mg/kg/day; divide doses if total daily dose exceeds 250 mg; oral.
Migraine Disorders 250 mg twice daily; some patients may benefit from doses up to 1,000 mg/day; oral.
Contraindications
- Serious hypersensitivity to fremanezumab-vfrm or any excipient, including anaphylaxis and angioedema
- Hepatic disease or significant hepatic dysfunction
- Mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age suspected of having a POLG-related disorder
- Known hypersensitivity to divalproex sodium, sodium valproate, or valproic acid
- Known urea cycle disorders
- Migraine prophylaxis in pregnant women or in women of childbearing potential not using effective contraception
Adverse Reactions
Most common (>=2%) Injection site reactions (pain, induration, erythema)
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Anaphylactic reactions, angioedema, hypertension, Raynaud's phenomenon
Most common (>=5%) Nausea, vomiting, somnolence, dizziness, tremor, asthenia, alopecia, headache, abdominal pain, dyspepsia, diarrhea, weight gain
Serious Hepatic failure, birth defects, pancreatitis, hyperammonemic encephalopathy, suicidal behavior and ideation, bleeding and hematopoietic disorders, hypothermia, DRESS/multiorgan hypersensitivity, serious dermatologic reactions, angioedema
Postmarketing Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, parkinsonism, aplastic anemia, pancytopenia, fractures, decreased bone mineral density, polycystic ovary disease, male infertility, angioedema
Pharmacology
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, thereby inhibiting CGRP-mediated signaling implicated in migraine.
Divalproex sodium dissociates to the valproate ion in the gastrointestinal tract; its therapeutic mechanisms have not been fully established, but its anticonvulsant activity is thought to relate to increased brain concentrations of gamma-aminobutyric acid (GABA).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ajovy
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (7/12) · Qty limit (10/12)
Depakote
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Ajovy
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (1/8)
Depakote
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Ajovy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Depakote
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Depakote.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DepakoteView full Depakote profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.